BriaCell Therapeutics Corp.
BCTXNasdaqCIK 1610820HealthcareFiscal year ends Jul 31
Reports and events: 149 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-06-2616:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-030286 |
| 2026-06-0916:06 ET | 10-Q | Quarterly reportPeriod 2026-04-30 | 0001493152-26-027928 |
| 2026-06-0321:32 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-026953 |
| 2026-03-3116:10 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-014156 |
| 2026-03-1017:08 ET | 10-Q | Quarterly reportPeriod 2026-01-31 | 0001493152-26-009557 |
| 2026-03-0916:52 ET | 8-K | 5.07 Shareholder vote results | 0001493152-26-009382 |
| 2026-02-2016:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-007587 |
| 2026-02-1216:00 ET | DEF 14A | Proxy statementPeriod 2026-02-12 | 0001493152-26-006390 |
| 2026-01-1516:15 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-002430 |
| 2025-12-2916:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-25-029363 |
| 2025-12-2308:21 ET | S-1 | Registration statement | 0001493152-25-028916 |
| 2025-12-1116:05 ET | 10-Q | Quarterly reportPeriod 2025-10-31 | 0001493152-25-027240 |
| 2025-12-0120:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-25-025469 |
| 2025-10-1620:46 ET | 10-K | Annual reportPeriod 2025-07-31 | 0001493152-25-018212 |
| 2025-08-2620:18 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001641172-25-025438 |
| 2025-07-1616:15 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001641172-25-019892 |
| 2025-07-1017:29 ET | S-1/A | Registration statement, amended | 0001641172-25-018633 |
| 2025-07-0913:05 ET | S-1/A | Registration statement, amended | 0001641172-25-018347 |
| 2025-07-0816:08 ET | S-1 | Registration statement | 0001641172-25-018193 |
| 2025-06-1808:27 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001641172-25-015516 |
| 2025-06-1616:34 ET | 10-Q | Quarterly reportPeriod 2025-04-30 | 0001641172-25-015265 |
| 2025-04-2816:15 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001641172-25-006428 |
| 2025-04-2316:51 ET | S-1/A | Registration statement, amended | 0001641172-25-005871 |
| 2025-04-2216:02 ET | S-1 | Registration statement | 0001641172-25-005677 |
| 2025-03-1216:22 ET | 10-Q | Quarterly reportPeriod 2025-01-31 | 0001493152-25-010052 |
| 2025-03-1216:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-25-010035 |
| 2025-02-1316:00 ET | 8-K | 8.01 Other events | 0001493152-25-006419 |
| 2025-02-0616:30 ET | 8-K | 5.07 Shareholder vote results | 0001493152-25-005204 |
| 2025-02-0517:02 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-005043 |
| 2025-01-2816:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-003977 |
| 2025-01-0317:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-000281 |
| 2025-01-0317:00 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-25-000282 |
| 2024-12-1716:05 ET | DEF 14A | Proxy statementPeriod 2024-12-17 | 0001493152-24-050399 |
| 2024-12-1616:05 ET | 10-Q | Quarterly reportPeriod 2024-10-31 | 0001493152-24-050214 |
| 2024-12-1616:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-050212 |
| 2024-12-1316:15 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-24-049999 |
| 2024-12-1206:06 ET | SC 13D/A | Ownership report, active investor, amended | 0001493152-24-049719 |
| 2024-12-1006:06 ET | SC 13D/A | Ownership report, active investor, amended | 0001493152-24-049352 |
| 2024-12-0507:45 ET | SC 13D/A | Ownership report, active investor, amended | 0001493152-24-048801 |
| 2024-11-2516:00 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001493152-24-047606 |
| 2024-11-0116:05 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-043322 |
| 2024-10-2918:22 ET | 10-K | Annual reportPeriod 2024-07-31 | 0001493152-24-042743 |
| 2024-10-0216:30 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-24-039218 |
| 2024-10-0116:02 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-24-039016 |
| 2024-09-1216:25 ET | 8-K | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-24-036055 |
| 2024-09-1108:50 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-24-035737 |
| 2024-08-2317:00 ET | 8-K | 3.01 Delisting notice | 0001493152-24-033753 |
| 2024-07-1816:30 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-24-028343 |
| 2024-07-0516:10 ET | 8-K | 3.01 Delisting notice | 0001493152-24-026349 |
| 2024-06-1416:10 ET | 10-Q | Quarterly reportPeriod 2024-04-30 | 0001493152-24-023867 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.